高复制HBV转基因小鼠模型对抗病毒药物拉米夫定评价的研究

Usage of HBV Transgenic Mice in Evaluation of Antiviral Drug Lamivudine

[目的]探讨乙型肝炎病毒(HBV)转基因小鼠模型筛选抗HBV药物的可行性。[方法]用公认抗HBV复制药物拉米夫定对我们建立高复制HBV转基因鼠进行实验,选我们建立的1.3copy高复制HBV转基因小鼠20只,随机分成两组,每组10只。采用灌胃针灌胃法给药。对照组灌喂生理盐水,实验组灌喂拉米夫定,剂量为100mg/kg,每天2次,连续灌21d,每7d采血1次。荧光定量PCR检测血清中HBVDNA。[结果]实验组用拉米夫定前小鼠血清HBVDNA5.50±0.42(拷贝数log10数值),3周后HBVDNA已显著降低(4.63±0.57),4周后,小鼠血清HBVNDA为4.08±0.51,停药1周后,再次检测血清HBVDNA,小鼠血清HBVDNA又恢复正常水平(5.70±0.39)。[结论]我们建立的高复制HBV转基因小鼠模型验证了拉米夫定对HBV复制的抑制程度和持续时间,表明该模型可应用于抗HBV药物的筛选、评价研究。

[Objective] To evaluate the feasibility of HBV transgenic mice in antiviral drug screening. [Methods] Twenty HBV transgenic mice were randomly divided into 8 groups, 10 in each group and drug was administered via stomach tube. The control group was given normal saline, the treat group was given oral solution of Lamivudine(3TC), 100mg/kg, twice a day for 21 days consecutively. Blood samples were collected once every 7 days, and the serum HBV DNA was detected by Fluorescent Quantitation PCR. [Results] In the ...